Changing epidemiology of invasive fungal infections.
George Petrikkos, MD,
Professor of Internal Medicine and Infectious Diseases
[email protected] National and Kapodistrian University of Athens
ATTIKON Hospital
12th ESCMID Summer School 6 – 13 July 2013, Vravrona, Greece
ESCMID Online Lecture Library
© by author
Transparency Declaration
• I have received research grants from Gilead, Pfizer, Astellas, and Astra-Zeneca
• Acted as paid consultant to MSD and Astellas
• Member of the MSD speaker’ s bureau
ESCMID Online Lecture Library
© by author
Incidence of Invasive Mycoses Time iC iA
1999 24 3.4
2000 23 4.1
2001 22 3.0
2002 23 2.6
2003 29 2.2
2004 27 2.4
Pfaller, ICAAC M 1805, 2006
Incidence per 100.000 population
ESCMID Online Lecture Library
© by author
Increasing rate of candidiasis in the US
Martin et al, NEJM 2003;348:1546
+300%
+300%
+600%
+300%
ESCMID Online Lecture Library
© by author
Increases in the prevalence of systemic Candida infections
Bassetti M, et al. BMC Infect Dis 2006; 6:21
Inci
den
ce o
f ca
nd
idae
mia
(e
pis
od
es/1
0,0
00
pat
ien
t-d
ays/
year
)
Year
1999 2000 2001 2002 2003
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
ESCMID Online Lecture Library
© by author
The Incidence of IFIs is increasing
Annual incidence rates for IFIs in patients with haematologic malignancies from 18 centres in Italy between 1999 and 2003
Pagano L et al. Haematologica. 2006;91:1068-1075.
0
1
2
3
4
5
6
1999 2000 2001 2002 2003
Year
Annu
al in
cide
nce
rate
s, %
Aspergillus spp
Other moulds
Candida spp
Other yeasts
All fungal agents
IFI = invasive fungal infection.
ESCMID Online Lecture Library
© by author
TRANSNET IFI Incidence July 2001-Dec 2005
0
5
1015
20
25
3035
40
45
Jul-Dec2001
Jan-Jun2002
Jul-Dec2002
Jan-Jun2003
Jul-Dec2003
Jan-Jun2004
Jul-Dec2004
Jan-Jun2005
Jul-Dec2005
ApergillosisFusariosisZygomycosis
•Cases/1000 transplants
ESCMID Online Lecture Library
© by author
Incidence of invasive fungal infections after stem cell transplant, in USA, 2001-2006
(TransNet)
1,6
1,1
0,3
00,20,40,60,8
11,21,41,61,8
Aspergillosis Candidiasis Zygomycosis
12-m
onth
cum
ulat
ive
inci
denc
e (%
)
Kontoyiannis DP. Clin Infect Dis. 2010;50:1091-1100.
ESCMID Online Lecture Library
© by author
Mortality due to invasive mycoses
0.6
0.4
0.2
0.0
1981 1986 1991 1996
Year
Rate
per
100 0
00 p
opulation
candidiasis
Other mycoses
aspergillosis
McNeil et al., Clin Infect Dis 2001:33
ESCMID Online Lecture Library
© by author
IFI Neutropenia
Radiation therapy
Cytotoxic chemotherapy
Immunosuppression cyclosporin, steroids
AIDS Damage to integument mucositis, surgery, devices
ICU
Chronic illness renal/liver failure
Age extremes
Alteration of microbial flora
Malnutrition
Malignancy
Factors predisposing to development of IFI
ESCMID Online Lecture Library
© by author
Populations at risk / risk factors
Immunocompromised “Non-immunocompromised” Neonates
Granulocytopenia Broad spectrum Abx In addition to ←
BMT Hemodialysis Gestational age
Mucositis CVC Low APGAR
GVHD IV drug use Length of NICU stay
Type of chemo Severity of illness H2 blockers
Organ transplants TPN Shock
Broad spectrum Abx GI perforation or surgery Intubation
CVC Colonization? GI disease
Colonization? Diabetes
LOS in ICU
Pancreatitis
Congenital malformations
Risk is an important factor when deciding who/when to treat! Blumberg HM et al. Clin Inf Dis 2001;33:177-86 Wenzel RP. Clin Inf Dis 1995; 20:1531-4 Fass RJ et al. J Antimicrob Chemother 1996;38:915-6
ESCMID Online Lecture Library
© by author
The medically most important opportunistic mycoses in Europe are caused by Aspergillus spp.
and Candida spp.
Aspergillus spp. A.fumigatus is the most common etiologic agent (80-90%), other species are A.flavus (10-15%), A.terreus (2-5%), A.niger (1-2%).
Candida spp. C. albicans, with an increasing incidence of
C. glabrata , C. tropicalis and C. krusei.
Kullberg et al. Epidemiology of opportunistic invasive mycosis. Europ. J Med. Research, 2002 ESCMID Online Lectu
re Library
© by author
Candidiasis C. albicans is a member of the indigenous microbial flora of humans. 1. Found in the gastrointestinal tract, upper respiratory tract, buccal
cavity, and vaginal tract. 2. Growth is normally suppressed by other microorganisms found in
these areas. 3. Alterations of gastrointestinal flora by broad spectrum antibiotics or
mucosal injury can lead to gastrointestinal tract invasion. 4. Skin and mucus membranes are normally an effective barrier but
damage by introduction of catheters or intravascular devices can permit Candida to enter the bloodstream. In vitro (25o C): mostly yeast;
In vivo (37o C): Yeast, hyphae and pseudohyphae
ESCMID Online Lecture Library
© by author
Exogenous transmission of Candida includes:
use of contaminated irrigation solutions
parenteral nutrition fluids
vascular pressure transducers
cardiac valves
corneas.
Transmission of Candida spp. from health care workers to patients and from patient to patient has been well documented, especially in ICU.
The hands of health care workers serve as potential reservoirs for nosocomial transmission of Candida spp.
ESCMID Online Lecture Library
© by author
Incidence of Candida bloodstream infections (per 10,000 hospital
admissions)
Canada 4.0
United States 8.0
Brazil 24.9
Australia 2.1
Spain 5.3
Sweden 3.2
France 2.0
Italy 3.8
Almirante et al. 2005; Colombo et al. 2005; Chen et al. 2006; Hajjeh et al. 2004; Laupland et al. 2005; Tortorano et al. 2004;
ESCMID Online Lecture Library
© by author
Candidaemia – Incidences Europe
Almirante 2005, Krcméry 2000, Kibbler , Boo 2005, Presterl 2007, Richet 2002, Marchetti 2004, Verduyn Lunel Neth 2006, Tortorano 2002, Odds 2007, Sandven 2006
0.19/1,000 FCE 6 Mixed hosp UK 1997-1999
4.3/100,000 Barcelona ES 2002-2003
0.34/1,000 adm Multi-centre CH 1991-2000
0.75/1,000 adm 5 Univ hosp NL 1996-2001
0.48/1,000 adm Multi-centre IR 1992-2003
0.29/1,000 adm 25 Mixed hosp FR 1998-2001
6.4/100,000 Lombardy IT 1997-1999
0.77/1,000 adm 1 Univ hosp AU 2006
1.2/100,000 National SK 1997-1998
4.8/100,000 Scotland 2006
3/100,000 Norway 2001-3
ESCMID Online Lecture Library
© by author
Nosocomial bloodstream infections in US hospitals: 1995-2002
(SCOPE study of 24,179 cases of nosocomial BSI in the US)
Rank
Pathogen
BSI per 10,000
admissions
% BSI % Crude mortality
Total n=20,978
ICU n=10,515
Non-ICU n=10,515
Total ICU Non-ICU
1. CoNS 15.8 31.3 35.9 26.6 20.7 25.7 13.8
2. S aureus 10.3 20.2 16.8 23.7 25.4 34.4 18.9
3. Enterococcus spp 4.8 9.4 9.8 9.0 33.9 43.0 24.0
4. Candida spp 4.6 9.0 10.1 7.9 39.2 47.1 29.0
5. E coli 2.8 5.6 3.7 7.6 22.4 33.9 16.9
6. Klebsiella spp 2.4 4.8 4.0 5.5 27.6 37.4 20.3
7. P aeruginosa 2.1 4.3 4.7 3.8 38.7 47.9 27.6
8. Enterobacter spp 1.9 3.9 4.7 3.1 26.7 32.5 18.0
9. Serratia spp 0.9 1.7 2.1 1.3 27.4 33.9 17.1
10. A baumannii 0.6 1.3 1.6 0.9 34.0 43.4 16.3
BSI=blood stream infection. Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) study.
ESCMID Online Lecture Library
© by author
Evolution of Isolation of Candida Species in Relation to Fluconazole Consumption
0
20
40
60
80
100
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003Year
Spe
cies
dis
trib
utio
n
Sendid B et al. BMC Infectious Diseases 2006:61-9.
C. albicans C. glabrata C. tropicalis C. parapsilosis C. krusei Other species
ESCMID Online Lecture Library
© by author
Candidemia in Bone Marrow Transplantation
30 patients with Candidemia
585 patients received Fluconazole prophylaxis 400 mg/d X 75 days
Colonization: 256 (44%)
Non-albicans in 53%
Rate of candidemia decreased: 11.4% to 4.6%
2/2 C. albicans Flu-R
Attributable mortality: 20%
Marr et al, JID, 2000
ESCMID Online Lecture Library
© by author
NEMIS Surveillance Hand Cultures
C. parapsilosis
59%
C. albicans
19%
C. lusitaniae
9.5%
C. guillermondii
6.3%
C. glabrata
2.9%
C. tropicalis
1.8%
Other Candida spp.
2.3%
C. krusei
0.6%
Species
% of total
N=2787 isolates
Rangel-Frausto/NEMIS. CID 1999;29:253
ESCMID Online Lecture Library
© by author
Biofilms and Candida parapsilosis
• 2nd most common species in blood, related to catheters and glucose solutions
• Causes biofilms which usually require removal of catheters etc, as antifungal drugs are ineffective in eradicating biofilms
Pfaller 2006, Pfaller 2007
ESCMID Online Lecture Library
© by author
Distribution of principal Candida species in Europe
Tortorano AM, et al. Eur J Clin Microbiol Infect Dis 2004; 23:317–22
C. albicans
C. glabrata
C. parapsilosis
C. tropicalis
C. krusei
C. guilliermondii
C. lusitaniae
C. kefyr
Other species
Unidentified Candida sp.
> 1 Candida spp.
Most common species: Candida albicans (44 – 62%, N. America, Europe)
C. glabrata is the 2ndor 3d (according to country )
most commonly isolated Candida species in Europe
ESCMID Online Lecture Library
© by author
In European countries : C. albicans (61 % of isolates)
U.Binder and C. Lass-Flörl. Mediterr J Hematol Infect Dis 2011; 3:
Region 1st 2nd 3d 4th
Switzerland, UK C. albicans C. glabrata
C. parapsilosis
C. tropicalis
South
C. albicans C. parapsilosis C. glabrata C. tropicalis
Spain
C. albicans C. parapsilosis C.tropicalis C. glabrata
Distribution of principal Candida species in Europe
ESCMID Online Lecture Library
© by author
1- Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., Biraghi E., Canton E., Zimmermann K., Seaton S., Grillot R. CMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004; 23(4):317-22.
Epidemiology of Candida species is complex and varies among different patient care units1
Causative Candida species by hospital care unit
Clinicians must consider their own units’ epidemiologic trends
Pathogens
ESCMID Online Lecture Library
© by author
Underlying conditions in patients with candidaemia
Underlying condition* Number of patients (%) Surgery 933 (44.7) Intensive care 839 (40.2)
Solid tumour 471 (22.5)
Haematological malignancy 257 (12.3) Premature birth 125 (6.0) Solid organ transplantation 74 (3.5) HIV infection 63 (3.0) Burns 29 (1.4) A total of 2,089 cases of candidaemia were documented by 106 institutions in the seven participating countries during the 28-month study period *364 (17.4%) were treated with steroids
Tortorano AM et al. Eur J Clin Microb Infect Dis 2004; 23: 317
ESCMID Online Lecture Library
© by author
Epidemiology of Candida species by underlying condition and age group
Category (n) Candida species
C. albicans C. glabrata C.
parapsilosis
C. tropicalis
Underlying condition Surgery (933) 58.0 16.3 12.6 6.1 Intensive care (839) 60.5 11.9 12.9 6.1 Solid tumour (471) 58.0 15.9 10.6 8.3 Haematological malignancy (257) 34.6* 9.7 14.8 17.9*
Foetal immaturity (125) 60.8 4.8* 28.8* 2.4 HIV infection (63) 65.1 9.5 6.3 6.3 Age group < 1 year (158) 59.6 3.1* 27.9* 3.1 1–19 years (144) 47.9 3.6* 32.9* 5.7 20–69 years (1,189) 57.1 14.0 11.2 8.3 ≥ 70 years (590) 60.0 19.3* 6.9* 7.1 Total population 56.4 13.6 13.3 7.2
Tortorano AM, et al. Eur J Clin Microbiol Infect Dis 2004; 23:317–22 *p ≤ 0.01 versus percentage in total
population.
ESCMID Online Lecture Library
© by author
1- Bille J.,Curr Opin Infect Dis. 2005;18(4):314-9. 2- Pfaller M.A., Diekema D.J. Clin Microbiol Infect. 2004;10 Suppl 1:11-23.
Epidemiology of Candida spp infection in Europe and USA
Candida spp. isolated in Europe2 (1992-2001; N = 775)
Candida spp. isolated in the U.S.2 (1992-2001; N = 3,683)
13%
C. glabrata
C. parapsilosis
C. tropicalis
C. glabrata
C. parapsilosis
C. tropicalis
Other non-albicans spp
14%
8%
5%
C. albicans 58%
18%
13%
10%
Other non-albicans spp
C. albicans 54%
C. krusei
3%
C. krusei
2%
Crit Care Med 2009; 37: 1612-18 IJAA 2009; 554:e1-7
2%
ESCMID Online Lecture Library
© by author
Pt Groups and Host Factors
No of cases 1,143 569 314 1,093
CVC 78% - <91% 73%
Surgery 50% 45% 56% 37%
ICU 36% 40% 51% 25%
SO Tumour 24% 23% 23% 16%
Haematological M. 11% 12% 9% 16%
Premature/Neonate 5% 6% 2.5% 3.3%
SO Transplant 5%* 3.5% 2.5% 2.2%
Burn - 1.4% 0% -
30 Days Mortality 36% 38% 38% 28%
Hajjeh JCM 2004, Tortorano Eur J Clin Micro Inf Dis 2004, Chen Emerg J Dis 2006
ESCMID Online Lecture Library
© by author
Distribution of principal Candida species in Europe Summary
• The epidemiology of Candida infections is changing so that the proportion of infections caused by C. albicans is decreasing while non-albicans species are becoming more common.1
• The largest increases have been seen in species that show acquired or intrinsic resistance to fluconazole, such as C. glabrata and C. krusei. In many studies, C. glabrata is now the second most commonly isolated Candida species after C. albicans.2
• These changes may be explained by increased fluconazole use and subsequent increases in colonisation by fluconazole-resistant species and may have significant clinical implications.3
• Fluconazole is the most commonly used antifungal agent, despite as many as 10–15% of C. glabrata and almost 75% of C. krusei infection-causing isolates being partially or completely resistant to it.2,4
1.Bassetti M, et al. BMC Infect Dis 2006; 6:21. 2.Tortorano AM, et al.. Eur J Clin Microbiol Infect Dis 2004; 23:317–322. 3.Trick WE, et al.. Clin Infect Dis 2002; 35:627–630. 4.Messer SA, et al. J Clin Microbiol 2006; 44:1782–1787.
ESCMID Online Lecture Library
© by author
Resistance to fluconazole in Candida spp.
Species
Fluconazole MIC (µg/ml)
Percentage of isolates
50% 90% Range Susceptible
Susceptible–dose-
dependent* Resistant
Candida spp. 0.5 16 ≤ 0.12–256
88.5 7.3 4.2
C. albicans ≤ 0.25
0.5 ≤ 0.12–128
99.4 0.1 0.4
C. glabrata 8 64 1–128 52.1 35.8 12.1 C.
parapsilosis
1 2 0.25–64 98.8 0.8 0.4
C. tropicalis 1 2 ≤ 0.12–128
98.0 0.7 1.3
C. krusei 64 128 16–256 0.0 25.9 74.1
Messer SA, et al. J Clin Microbiol 2006; 44:1782–1787 *Refers to isolates with reduced susceptibility that
can be overcome by increasing the dose.
ESCMID Online Lecture Library
© by author
Candida glabrata
• Sub-optimal fluconazole dosing
• Pan-azole resistance
• Over 10 years, the frequency of C. glabrata increased in
– Canada, 13-24%
– Europe, 11-13%
– USA, 14-28%
• Least common in Latin America (7.5%)
Pfaller 2006, Bhatti 2006, Pfaller 2007
ESCMID Online Lecture Library
© by author
Aspergillus & other moulds
ESCMID Online Lecture Library
© by author
Aspergillus
•Ubiquitous mould:
•Soil, water, decaying vegetation
•Sources
•Unfiltered air/ventilation systems •Dust from renovation/construction •Environmental sources •Food/plants
ESCMID Online Lecture Library
© by author
Environment as a Risk Factor Fungus at Home
• Hospital construction is known to increase cases of IA
• HEPA filtration is known to decrease cases of IA
• Aspergillus may be found in patient showers… genetically identical to the one from the patient!
• Highest concentration of Aspergillus fumigatus is at home
• Protective environment for pts with allo-BMT now included in the new draft CDC guidelines for isolation
Williamson, Thorax 1997;52:229.
Taskinen, Acta Paediatr 1999; 88:1373.
Oren, Am J Hematol 2001; Anaissie, CID 2002.
ESCMID Online Lecture Library
© by author
Environment as a risk factor
• Hospital construction is known to increase cases of IA
• HEPA filtration is known to decrease cases of IA
• Aspergillus may be found in patient showers… genetically identical to the one from the patient!
• Protective environment for pts with allo-BMT now included in the new draft CDC guidelines for isolation
Oren, Am J Hematol 2001; Anaissie, CID 2002.
Invasive Aspergillosis
ESCMID Online Lecture Library
© by author
Aspergillus and Construction
•Association between aspergillosis outbreaks and construction •Environmental controls associated with decreased risk
•Maintain positive pressure
•Install appropriate barriers •Control traffic in construction areas •Monitoring of airborne spore count
Arnow 1991; Wald 1997; Cornet 1999; Patterson 2000
ESCMID Online Lecture Library
© by author
Dust Control - Contractor Issues
ESCMID Online Lecture Library
© by author
Dust Control - Maintenance Issues
ESCMID Online Lecture Library
© by author
ADMISSION TO THE HUMAN BODY
•Aspergillus is clearly mainly an airborne infection, the spores in the air will enter the body through the airways and they will arrive CLIK in nasal sinuses and bronchi where the first lesions are usually found.
ESCMID Online Lecture Library
© by author
Classic risk factors for aspergillosis
• Hematological malignancies
– Leukemia
– MDS
– SCT
– GVHD
– Prolonged neutropenia
– Induction chemo
• Critically ill?
• Immunosuppression, Steroids
• HIV/AIDS?
• Transplant patients:
– Lung, liver, heart, renal
– Liver transplant
– Acute/ chronic rejection
– Steroids
– Tacrolimus
– OKT3
– Renal failure
– CMV
Muhlemann K, Leukemia. 2005 Feb 24; Sole A, Clin Microbiol Infect. 2005 May;11(5):359-65; Nina Singh N, Clin Microbiol Rev. 2005 Jan;18(1):44-69; Thursky K, Bone Marrow Transplant. 2004 Jul;34(2):115-21.
ESCMID Online Lecture Library
© by author
Invasive Aspergillosis in Transplant Recipients
Type of Transplant Incidence Range, % (Mean) Mortality (%)
Lung 3-14% (6%) 68%
Liver 1-8 (2) 87
Heart 1-15 (5) 78
Kidney 0-4 (1) 77
Small bowel 0-10 (2) 66
Allogeneic stem cell 5-26 (10) 78-92
Autologous stem cell 2-6 (5) 78-92
Nonmyeloblative stem cell 8-23 (11) 63-67
Singh & Paterson. Clin Microbiol Rev. 2005 18:44-69.
ESCMID Online Lecture Library
© by author
TRANSNET Aspergillus Isolates 2001-2004
A.terreus9%Other*
5%
A.niger10%
A.flavus13%
A. Fumigatus63%
*Other includes A versicolor, A ustus, A glaucus, A nidulans, and A ilacinus.
Adapted from Baddley JW, et al. IDSA . 2004. Abstract 673.
ESCMID Online Lecture Library
© by author
The Changing Landscape of Fungal Infections: Increasing Apergillosis and Other Molds
• An increase in aspergillosis and decrease in candidiasis has been observed:
– 2 large autopsy studies
– Study of bone marrow transplant recipients
• A similar pattern has been reported in a pediatric cancer population
Groll A et al. J Infect 1996:23-32. Yamazaki T et al. J Clin Microbiol 1999;1732-1737. van Burik J et al. Medicine 1998:246-254. Rosen G et al. J Pediatr Hematol Oncol 2005:135-140.
ESCMID Online Lecture Library
© by author
Invasive Aspergillosis Continues to Pose a Significant Threat
• In Germany, a review of 11,000 autopsy cases from 1978 through 1992 demonstrated a 17-60% proportional increase in cases of invasive aspergillosis.
• In the US, the number of deaths due to aspergillosis increased almost 4-fold between 1980 and 1997.
• When stratified by underlying disease, patients with bone marrow transplants have a case mortality of 87-90%, the highest rate observed for any group.
Kullberg B, Lashof O. European J Med Res. 2002;7:183-191.
ESCMID Online Lecture Library
© by author
Aspergillosis at Autopsy - Sites of Infection
Disseminated
Lungs only
CNS only
Disseminated (not lungs)
Vogeser et al Eur J Clin Microbiol Infect Dis 1999;18; 42-45
ESCMID Online Lecture Library
© by author
0
10
20
30
40
50
60
70
80
90
Underlying condition Site of infection
Overall BMT Leukaemia lymphoma
Pulmonary CNS Disseminated
Crude mortality for invasive aspergillosis Review of the literature - 1941 patients from 50 studies
(1118/1941)
(247/285)
(142/288)
(74/84)
(97/161)
Lin et al
ESCMID Online Lecture Library
© by author
Author Year Type of study Patient category N. Incidence Mortality
Lewis 1985 Case series IPA complicating influenza pneumonia
Case report and literature review 6 - 100%
Karam 1986 Cases series Non-neutropenic patients - 10 structural lung disease
7 steroid treatment
32 - 100%
Janssen JJWM
1996 Monocentric
Retrospective Medical ICU pts with hematological malignancy, immunosuppression for mixed connective tissue disease, ARDS
25 - 92%
Pittet 1996 COPD patients in MICU
Acquisition of IPA during mechanical ventilation due to high grade airborne inoculation
2 - 100%
Rello 1998 Monocentric Series of COPD patients and literature review
24 - 100%
Valles 2002 Two centres
Observational, prospective study
Hospital acquired pneumonia requiring ICI admission
Aspergillus spp. identified in 17% of pts Mainly COPD pts
77%
Bulpa 2001 Monocentric
Case series COPD patients admitted to ICU diagnosed with IPA
23 - 100%
Epidemiological studies on Aspergillosis in ICU
ESCMID Online Lecture Library
© by author
Author Year Type of study Patient category N. Incidence Mortality
Meersseman 2004 Monocentric
Retrospective Medical ICU
70% cases without malignancy
5 pts with IA without known predisposing condition (of whom 3 Child C cirrhosis)
107 5.8% 91%
Garnacho-Montero
2005 Multicentric
Prospective 73 ICU’s in Spain
patients with LOS > 7 days 20 1.1% 80%
Vandewoude 2006 Retrospective Mixed ICU 40% haematological pts
83 3.3/ 1000
77%
Epidemiological studies on Aspergillosis in ICU
ESCMID Online Lecture Library
© by author
ESCMID Online Lecture Library
© by author
Cryptococcosis
ESCMID Online Lecture Library
© by author
Epidemiology of Cryptococcosis Mainly: Cryptococcus neoformans (associated with HIV or other immunosuppression, cosmopolitan, pigeon excrement)
Cryptococcus gattii (previous name C. neoformans var. gattii, associated with recent epidemics in immunocompetent in British Columbia, Canada and the Pacific Northwest, tropical and subtropical climates, eucalyptus trees)
ESCMID Online Lecture Library
© by author
Epidemiology of Cryptococcosis
Cryptococcosis is usually acquired by inhaling aerosolized cells of C. neoformans from the environment, disseminate from lungs to CNS.
pathogenic for immune-competent individuals, but most often encountered as “opportunistic pathogen”.
the most common cause of fungal meningitis and tends to occur in patients with defective cellular immunity (HIV).
HIV patients with CD4+ T less than 200/mm3 are at high risk for CNS and disseminated cryptococcosis.
ESCMID Online Lecture Library
© by author
Western & Central Europe
500
North Africa & Middle East
6,500 Sub-Saharan
Africa 720,000
Eastern Europe & Central Asia
27,200
South & South-East Asia
120,000 Oceania
100
North America 7,800 Caribbean
7,800 Latin America
54,400
East Asia 13,600
Global total: 957,900 cases (range: 371,700 – 1,544,000)
Estimated annual cases of HIV-associated cryptococcosis
Park et al. AIDS 2009; 23: 525-30
ESCMID Online Lecture Library
© by author
Western & Central Europe
45
North Africa & Middle East
3,600 Sub-Saharan
Africa 504,000
Eastern Europe & Central Asia
15,000
South & South-East Asia
66,000 Oceania
10
North America 700 Caribbean
4,300 Latin America
29,900
East Asia 1,200
Global total: 624,700 deaths (range: 125,000 – 1,124,900)
Estimated annual deaths from HIV-associated cryptococcosis
Park et al. AIDS 2009; 23: 525-30
ESCMID Online Lecture Library
© by author
0
200.000
400.000
600.000
800.000
1.000.000
1.200.000
Malaria
Diarrhe
al dis
ease
s
Childh
ood-c
luster
dise
ases
Cryptoc
occo
sis
Tuberc
ulosis
STDs exc
luding
HIV
Tropica
l-clus
ter di
seas
es
Hepati
tis B
Non-C
rypto
Mening
itis
Hepati
tis C
Estimated deaths in Sub-Saharan Africa from cryptococcosis and other infectious
diseases*
WHO estimates
* Excluding HIV AIDS
ESCMID Online Lecture Library
© by author
“The Others…”
ESCMID Online Lecture Library
© by author
Rare fungal infections Changing epidemiology
ESCMID Online Lecture Library
© by author
Rare fungi increasingly encountered as causing disease:
Zygomycetes (mucorales) Hyaline filamentous fungi: Fusarium spp., Pseudallescheria boydii /Scedosporium Acremonium spp. Paecilomyces spp. Dematiaceous filamentous fungi: Bipolaris spp., Cladophialophora bantiana, Exophiala species Alternaria
mucormycosis
pheohyphomycosis
hyalohyphomycosis
ESCMID Online Lecture Library
© by author
Non-aspergillus moulds in SCT; FHCRC, Seattle
Marr KA, et al. Clin Infect Dis. 2002;34:909-917
Fusarium species 16
14
12
10
8
6
4
2
0
1985-1989 1990-1994 1995-1999
Time period
Zygomycetes
Scedosporium species
Inf
ect
ions
, n
ESCMID Online Lecture Library
© by author
Kaplan-Meier curve showing probability of survival for 53 transplant recipients with various types of mold infections
(Pp.153, by the Mantel-Cox test).
ESCMID Online Lecture Library
© by author
Epidemiology of Mucormycosis
ESCMID Online Lecture Library
© by author
Mode of transmission
Spores-Conidia
Trauma /inoculation
Respiration
ESCMID Online Lecture Library
© by author
Zygomycosis: Epidemiology
• The incidence of Zygomycosis is approximately 1.7 cases per 1 000 000 inhabitants per year, which means 500 patients per year in the USA.1
• Post-mortem evaluation shows that zygomycosis is 10- to 50-fold less frequent than candidiasis or aspergillosis, and it appears one to five cases per 10 000 autopsies.2-4
• In patients undergoing allogenic bone marrow transplantation the incidence may be 2-3%.5,6
1. Ree JR et al. Clin Infect Dis ; 27:1138-1147;1998. 2. Hotchi M et al. Am J Clin Pathol ;74:410-416;1980. 3. Tietz HJ et al. Mycosis (suppl 2); 81-85;1998. 4.Yamazaki T et al. J Clin Microbiol ; 37: 1732-1738;1999. 5. Maertens J et al. Bone Marrow Transplant ; 24:307-312;1999. 6. Marty FM et al . N Eng J Med ; 350:950-952
ESCMID Online Lecture Library
© by author
Changing Spectrum of Invasive Molds
Invasive Aspergillosis
64%
Fusariosis16%
Zygomycosis20%
Incidence per 1000 Patient Days
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
2000 2001 2002 2003 200
Year
Rat
e of
asp
ergi
llosi
s
0
0,03
0,06
0,09
0,12
0,15
0,18
0,21
Rat
e of
Zyg
omyc
osis
Aspergillus
Zygomycetes
Kontoyiannis DP, et al. J Infect Dis. 2005;191:1350-1360.
ESCMID Online Lecture Library
© by author
0%
20%
40%
60%
80%
100%
1940s 1950s 1960s 1970s 1980s 1990s 2000s
Per
cen
tag
e o
f zyg
om
yco
sis
case
s d
ocu
men
ted
by
cultu
re
Roden M, et al. Clinical Infectious Diseases 2005; 41:634–53
Mucormycosis has emerged as an increasingly important infection with high mortality.
Introduction
ESCMID Online Lecture Library
© by author
Patterns of Zygomycosis
4%10%
5%
60%
12%
3% 6%
Roden M, et al. Clinical Infectious Diseases 2005; 41:634–53
Malignancy
Rhinocerebral Sinus Sino-orbital Pulmonary Cutaneous Gastrointestinal Other
40%
8%14%
15%
9%
8%6%
Diabetes
7%9%
5%
8%
50%
9%
8% 4%
No Underlying Condition
Most of zygomycotic infections occur in patients with underlying diseases.
In a review of 929 zygomycosis cases, approximately 20% occurred in healthy individuals, but the most common reported cases were in those with diabetes, followed by cancer and bone marrow transplantation.
ESCMID Online Lecture Library
© by author
REVIEW OF THE LITERATURE (More than 5 Cases in Europe)
1. G.Petrikkos . Eur J. Clin Microbiol. and Inf. Dis. 2003 24 cases. Greece 2. M. Torres Narbona. J. Clin. Microbiol. 2007 6 cases Spain 3. L. Pagano. Journal of Chomother. 2009. 60 cases. Italy 4. D.Bitar. Emerg Infect Dis 2009. 531 cases France 5. M Ruping J . Animicrob. Chemother 2009. 41 cases Germany 6. J. Abrosioni. Int . J. Infect. Dis. 2010. 55 cases Switzerland 7. V. Saegeman Emerg Infect Dis. 2010 31 cases Belgium
ESCMID Online Lecture Library
© by author
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on
Zygomycosis between 2005 and 2007
• Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G; European Confederation of Medical Mycology Working Group on Zygomycosis.
Clin Microbiol Infect. 2011 Dec;17(12):1859-67.
ESCMID Online Lecture Library
© by author
9
21
60
1
2
2
36
35
6 5
12
16
2
0 1
0
22 0
60
36
35
22
21
16
12
9
6
5
2
2
2
1
1
Italy
Greece
Germany
Switzerland
France
Belgium
Austria
Spain
Russia
Norway
Finland
Czech Republic
Turkey
Netherlands
UK
0
Clin Microbiol Infect. 2011 Dec;17(12):1859-67.
ESCMID Online Lecture Library
© by author
Sites of infection in relation to underlying disease
Hematological malignancies (102)
p< 0.001
pulmonary34%
rhinocerebral
15%sinusitis
13%
soft tissue10%
disseminated
27%
liver1%
rhinocerebral52%
sinusitis10%
soft tissue14%
pulmonary14%
disseminated10%
soft tissues89%
sinusitis5%
pulmonary6%
Immunocompetent (18)
Diabetes (21)
Clin Microbiol Infect. 2011 Dec;17(12):1859-67.
ESCMID Online Lecture Library
© by author
RESULTS: Underlying disease in relation to the site of infection
Hem. malignancy correlated with pulmonary disease
– Of the 103 patients with hematological malignancy , 35 had pulmonary zygomycosis (33.98%)
– Of the 67 patients with pulmonary zygomycosis , 35 had an underlying hematological malignancy (52.24%)
Diabetes correlated with rhinocerebral disease
– Of the 21 patients with diabetes, 11 had rhinocerebral disease (52.38%)
– Of the 31 patients with rhinocerebral disease, 11 had diabetes (35.48%)
Pearson chi2 p<0.001
Clin Microbiol Infect. 2011 Dec;17(12):1859-67.
ESCMID Online Lecture Library
© by author
RESULTS: Underlying Diseases and mortality (%)
0
10
20
30
40
50
60
70
80
Underlying
Mortality
Clin Microbiol Infect. 2011 Dec;17(12):1859-67.
ESCMID Online Lecture Library
© by author
Mortality rates according to the site of infection
Phinocerebral 40-50%
Pulmonary 80%
Soft tissue Better prognosis
ESCMID Online Lecture Library
© by author
Mortality Due to Mold Infections
42,0%
64,0%
52,0%
0%
20%
40%
60%
80%
100%
Aspergillus spp Zygomycetes Fusarium spp
% o
f pat
ient
s
Pagano L et al. Haematologica 2006;91:1068-1075.
11,802 patients (18 centers)
ESCMID Online Lecture Library
© by author
CONCLUSIONS
• In conclusion, this large European study found that zygomycosis continues to be a disease with a dismal prognosis in about half of the cases.
• Clinicians treating patients with diabetes, haematological malignancies or trauma, or patients who are immunosuppressed for any reason, should have a high index of suspicion for the disease and make every effort to obtain tissue for histology, culture and, if possible, PCR.
• A combination of liposomal amphotericin B with surgery offers the best chance of recovery.
ESCMID Online Lecture Library
© by author
A.Skiada et al. for the European Confederation of Medical Mycology Working Group on Zygomycosis. Clin Microbiol Infect. 2011
Mucormycosis Underling diseases
Differences Between Europe and India
Trauma/no underlying
dis. 18%
Diabetes 15%
Haematol. malignancy
50%
SO Ca/T 8%
DFO 1%
Cortico 6%
HIV 2%
Skiada et al. 2011 Trauma/no underlying
dis. 20%
Diabetes 78%
Haematol. Malignancy
1%
SO Ca/T 1%
Chakrabarti et al. 2006
ESCMID Online Lecture Library
© by author
Variables that Account for the Current Trends in the Epidemiology
• Increasing number of susceptible hosts: transplant type
• Center to center differences, patient selection
• Greater laboratory expertise in detection & identification of fungi
• Use of new transplant modalities for hematopietic stem cell transplantation
• Changing surgical techniques: evolution in organ transplant practices
• Use of corticosteroid-sparing regimens and overall conservative approach to immunosuppression
• Use of novel immunosuppressive agents
• Antimicrobial prophylactic practices
• Underlying Diseases
• Poor diagnostic tools
Singh 2001; Denning 2005, Kontoyiannis 2005, Lass-Flörl 2005
ESCMID Online Lecture Library
© by author
Principal changes in the epidemiology of invasive fungal infection
J.J. Cast΄on-Osorio et al. / International Journal of Antimicrobial Agents 32 Suppl. 2 (2008) S103–S109
ESCMID Online Lecture Library
© by author
And the Epidemiology is changing Candida and Aspergillus species are the leading causes of
IFI in patients with hematological malignancies
Candida Data from 311 hospitals from 1989 to 1999 have demonstrated that:
– Bloodstream infections caused by C albicans have significantly decreased (P < .001)1
– Bloodstream infection caused by C glabrata have significantly increased (P = .05)1
– Data from TRANSNET reported that C. glabrata accounts for 32% of infections whereas C. albicans accounts for only 22% of infections2
increased prophylactic use of azoles and widespread use of antifungal agents for febrile neutropenia
prolonged echinocandin treatment
1. Trick WE et al. Clin Infect Dis. 2002;35:627-630.
2. Pappas PG. Focus on Fungal Infections 2007.
ESCMID Online Lecture Library
© by author
Invasive Aspergillosis occurs in 20% of Allogeneic HSCT, 10% of AML, 5% of ALL and 2% of Autologous HSCT
- Increase in 2006 : 40 cases per 1000 transplants
- Improvement of survival rates from 2001 to 2006
Zygomycetes: Data from the US Transplant-Associated Infection Surveillance Network (TRANSNET) have demonstrated that:
- Incidence of zygomycosis per thousand HCTs has increased from
1.7 in 2001 to 6.2 in 20041
- By early 2006, approximately 24% of all invasive mould infections
in the transplant population were caused by the Zygomycetes2
Prolonged use of voriconazole (prophylaxis or treatment)?
Fusarium and Scedosporium species: important etiologic agents 3
1. Park BJ et al. ICAAC 2007
2. Pappas PG. Focus on Fungal Infections 2007. 3. Upton A , Mark KA 2006.
And the Epidemiology is changing
ESCMID Online Lecture Library
© by author
Changing Epidemiology of Invasive Mycoses Summary
• Invasive mycoses remain a major cause of morbidity and mortality in high risk patients
• Aspergillus, Candida and Cryptococcus are major etiologic agents.
• The epidemiology of Candida infections is changing so that the proportion of infections caused by C. albicans is decreasing while non-albicans species are becoming more common.
• Incidence and clinical presentation of invasive mycoses differ in transplantation groups and in other immunosuppressed hosts.
• Other opportunistic moulds (Mucorales) may also be important pathogens in haematologic and diabetic patients.
• Any fungi isolated from immunocompromised patients should be considered as pathogens.
ESCMID Online Lecture Library
© by author
Remember:
• ‘Until we can show that the apparent size of the mycoses problem is deceptively small,
• ‘that in reality the mycoses are common diseases, and that the toll they take in misery and mortality is high,
• ‘we cannot expect to obtain the support we need for research and development’
Libero Ajello 1970
ESCMID Online Lecture Library
© by author
Zygomyco.net: an ECMM/ISHAM registry
ESCMID Online Lecture Library
© by author